Skip to content

Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System

A Study of Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03810833
Enrollment
12
Registered
2019-01-22
Start date
2019-09-16
Completion date
2019-09-23
Last updated
2020-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Keywords

Glomerular Filtration Rate

Brief summary

This study is designed to evaluate background fluorescence of participants of different ages, gender, and skin color. In addition, 48-hour tolerability of the sensor and adhesive will be evaluated.

Detailed description

The MediBeacon Transdermal GFR Measurement System investigational is intended to measure the Glomerular Filtration Rate (GFR) in patients with normal or impaired renal function by noninvasively monitoring fluorescent light emission from an exogenous tracer agent (MB-102) over time. The device utilized in this study is the Brilliance device. Approximately 1 male and 1 female from each age cohort (18-50 years; 51+ years) and clustered Fitzpatrick Skin Scale groups (I-II \[Light, pale white; white, fair\]; III-IV \[Medium, white to olive; olive, moderate brown\]; and V-VI \[Brown, dark brown; black, very dark brown to black\]) will be recruited, for a total of 12 participants. Participants will have Brilliance device sensors placed on two locations on their skin, which will remain for 48 hours. The sensor location will be prepared through shaving and cleaning (as applicable), placed on the skin via standard single-use adhesive pads, and baseline measurements collected. Participants may undergo activities of daily living while measurements are being collected. Light pressure and other minor perturbations may be applied to the sensors to evaluate the effect on background fluorescence. Adverse events associated with sensor placement (such as skin irritations) will be recorded.

Interventions

DEVICEBrilliance device sensor

Two separate sensors will be attached via standard, single-use adhesive pads to the left and right pectoralis major on each participant.

Sponsors

MediBeacon
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy male and female adults age 18 and older * 2 age cohorts to be recruited: 18 - 50 years of age and 51+ years or older * Skin color groups to be recruited in accordance with the Fitzpatrick Skin Scale (I - VI) * Participants willing to sign the Institutional Review Board (IRB) approved informed consent form prior to the initiation of any study specific procedures.

Exclusion criteria

* History of skin sensitivity to adhesives (e.g. Band-Aids, surgical tape) * Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial * Significant scarring, tattoos or alterations in pigmentation on the standardized sensor locations that would alter sensor readings versus other areas of the skin

Design outcomes

Primary

MeasureTime frameDescription
Mean Background FluorescenceFrom the time of sensor placement to 48 hours after placementTwo separate Brilliance device sensors will be attached via standard adhesive pads to the left and right pectoralis major on each participant. Fluorescence measurements will be collected directly by the MediBeacon Transdermal GFR Measurement System Brilliance device, and will be continuously collected throughout the 48 hour study.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026